See more : WildBrain Ltd. (WILD.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Lombard Medical, Inc. (EVARF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lombard Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- China Youzan Limited (8083.HK) Income Statement Analysis – Financial Results
- Sichuan Tianwei Electronic Co.,Ltd. (688511.SS) Income Statement Analysis – Financial Results
- RCL Foods Limited (RCL.JO) Income Statement Analysis – Financial Results
- ZIVO Bioscience, Inc. (ZIVO) Income Statement Analysis – Financial Results
- GuiZhou YongJi Printing CO.,LTD (603058.SS) Income Statement Analysis – Financial Results
Lombard Medical, Inc. (EVARF)
About Lombard Medical, Inc.
Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The company's principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement. Lombard Medical, Inc. sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals. The company was founded in 2000 and is headquartered in Didcot, the United Kingdom.
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | 12.17M | 15.11M |
| Cost of Revenue | 11.21M | 8.56M |
| Gross Profit | 955.00K | 6.56M |
| Gross Profit Ratio | 7.85% | 43.38% |
| Research & Development | 7.48M | 11.02M |
| General & Administrative | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 |
| SG&A | 22.81M | 35.01M |
| Other Expenses | 0.00 | 0.00 |
| Operating Expenses | 30.29M | 46.02M |
| Cost & Expenses | 41.50M | 54.58M |
| Interest Income | 93.00K | 134.00K |
| Interest Expense | 2.31M | 860.00K |
| Depreciation & Amortization | 2.14M | 1.80M |
| EBITDA | -28.07M | -37.36M |
| EBITDA Ratio | -223.49% | -249.23% |
| Operating Income | -29.34M | -39.47M |
| Operating Income Ratio | -241.06% | -261.13% |
| Total Other Income/Expenses | -805.00K | -726.00K |
| Income Before Tax | -32.52M | -40.02M |
| Income Before Tax Ratio | -267.20% | -264.78% |
| Income Tax Expense | -1.48M | -2.22M |
| Net Income | -31.04M | -37.80M |
| Net Income Ratio | -255.03% | -250.13% |
| EPS | -1.54 | -2.13 |
| EPS Diluted | -1.54 | -2.13 |
| Weighted Avg Shares Out | 20.17M | 17.76M |
| Weighted Avg Shares Out (Dil) | 20.17M | 17.76M |
Source: https://incomestatements.info
Category: Stock Reports